loading
Bristol Myers Squibb Co stock is traded at $47.92, with a volume of 11.57M. It is down -1.05% in the last 24 hours and down -0.21% over the past month. Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$48.43
Open:
$48.84
24h Volume:
11.57M
Relative Volume:
0.91
Market Cap:
$97.54B
Revenue:
$47.70B
Net Income/Loss:
$5.07B
P/E Ratio:
19.32
EPS:
2.48
Net Cash Flow:
$14.58B
1W Performance:
-1.07%
1M Performance:
-0.21%
6M Performance:
-14.17%
1Y Performance:
+0.63%
1-Day Range:
Value
$47.72
$49.11
1-Week Range:
Value
$47.72
$49.58
52-Week Range:
Value
$42.96
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Name
Bristol Myers Squibb Co
Name
Phone
(609) 252-4621
Name
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Employee
34,100
Name
Twitter
@BMSNEWS
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
BMY's Discussions on Twitter

Compare BMY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
47.92 98.09B 47.70B 5.07B 14.58B 2.48
Drug Manufacturers - General icon
LLY
Lilly Eli Co
711.68 625.77B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
179.29 424.47B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
210.60 364.92B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
126.98 240.07B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.37 210.36B 63.43B 16.42B 14.72B 6.49

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-05-25 Downgrade Daiwa Securities Outperform → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Apr-22-25 Initiated Piper Sandler Overweight
Dec-16-24 Upgrade Jefferies Hold → Buy
Dec-10-24 Resumed BofA Securities Neutral
Nov-15-24 Initiated Wolfe Research Peer Perform
Nov-13-24 Upgrade Daiwa Securities Neutral → Outperform
Nov-12-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-25-24 Downgrade Citigroup Buy → Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Jul-29-24 Downgrade Barclays Overweight → Equal Weight
Mar-11-24 Downgrade Societe Generale Buy → Hold
Feb-06-24 Downgrade Redburn Atlantic Buy → Neutral
Jan-03-24 Downgrade BofA Securities Buy → Neutral
Nov-15-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Nov-09-23 Initiated Deutsche Bank Hold
Nov-02-23 Downgrade Daiwa Securities Outperform → Neutral
Oct-27-23 Downgrade BMO Capital Markets Outperform → Market Perform
Oct-27-23 Upgrade HSBC Securities Reduce → Hold
Oct-27-23 Downgrade William Blair Outperform → Mkt Perform
Oct-20-23 Resumed UBS Neutral
Jul-14-23 Initiated HSBC Securities Reduce
Jul-10-23 Initiated SVB Securities Market Perform
Jun-28-23 Initiated Daiwa Securities Outperform
Mar-06-23 Initiated Jefferies Hold
Jan-17-23 Initiated Cantor Fitzgerald Overweight
Nov-18-22 Initiated Credit Suisse Neutral
Oct-10-22 Downgrade Guggenheim Buy → Neutral
Sep-14-22 Downgrade Berenberg Buy → Hold
Jun-03-22 Downgrade Raymond James Outperform → Mkt Perform
Apr-06-22 Resumed Morgan Stanley Underweight
Dec-17-21 Initiated Goldman Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Nov-01-21 Downgrade Argus Buy → Hold
Jul-27-21 Resumed Truist Buy
Apr-30-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-13-21 Upgrade Truist Hold → Buy
Nov-16-20 Upgrade Societe Generale Hold → Buy
Nov-10-20 Resumed Bernstein Mkt Perform
Nov-06-20 Downgrade Gabelli & Co Buy → Hold
Oct-19-20 Upgrade Guggenheim Neutral → Buy
Sep-29-20 Initiated Berenberg Buy
Jul-28-20 Initiated Raymond James Outperform
Apr-02-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Jan-06-20 Resumed Citigroup Buy
Dec-13-19 Upgrade Argus Hold → Buy
Nov-22-19 Resumed Morgan Stanley Equal-Weight
Oct-17-19 Resumed BofA/Merrill Buy
Aug-14-19 Upgrade Atlantic Equities Neutral → Overweight
May-28-19 Initiated Goldman Buy
May-20-19 Downgrade Argus Buy → Hold
May-03-19 Upgrade Barclays Equal Weight → Overweight
May-03-19 Resumed JP Morgan Overweight
Jan-15-19 Upgrade Societe Generale Sell → Buy
Oct-22-18 Downgrade Citigroup Buy → Neutral
View All

Bristol Myers Squibb Co Stock (BMY) Latest News

pulisher
Aug 20, 2025

Agilent, Bristol Myers win FDA nod for cancer test (A:NYSE) - Seeking Alpha

Aug 20, 2025
pulisher
Aug 20, 2025

Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.

Aug 20, 2025
pulisher
Aug 19, 2025

Bristol Myers Squibb Stock Surges on FDA Breakthrough Designation for Lung Cancer Drug Despite Ranking 217th in Trading Volume - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

Aug 19, 2025
pulisher
Aug 19, 2025

Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan... - Medical Dialogues

Aug 19, 2025
pulisher
Aug 19, 2025

Bristol Myers Squibb's Lung Cancer Drug Secures FDA Breakthrough Status - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Bristol Myers Squibb Company stock outlook for YEAR2025 Volume Leaders & AI Driven Stock Movement Reports - Newser

Aug 19, 2025
pulisher
Aug 18, 2025

Israel issues first antitrust fine to a global pharmaceutical company - Global Competition Review

Aug 18, 2025
pulisher
Aug 18, 2025

FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb - Enidnews.com

Aug 18, 2025
pulisher
Aug 18, 2025

Bristol Myers and SystImmune’s lung cancer drug gets FDA boost - Investing.com

Aug 18, 2025
pulisher
Aug 18, 2025

The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific - Yahoo Finance

Aug 18, 2025
pulisher
Aug 18, 2025

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times

Aug 18, 2025
pulisher
Aug 17, 2025

Bristol Myers (BMY) Partners with Bain Capital to Create Immunology Therapies - uk.finance.yahoo.com

Aug 17, 2025
pulisher
Aug 16, 2025

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS - Benzinga

Aug 16, 2025
pulisher
Aug 15, 2025

Lowe's, Bristol-Myers, and Marvell Technology: Key Research Reports - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Top Research Reports for Lowe's, Bristol-Myers & Marvell Technology - Yahoo Finance

Aug 15, 2025
pulisher
Aug 15, 2025

Bristol-Myers Squibb’s Promising Phase 3 Alzheimer’s Study: Market Implications - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Bristol-Myers Squibb’s New Study on NSCLC Treatment: Market Implications - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace

Aug 15, 2025
pulisher
Aug 14, 2025

Bristol-Myers Squibb’s Promising Phase 3 Study on Deucravacitinib for Sjögren’s Syndrome - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Bristol-Myers Squibb and Incyte’s Cancer Study Update: Market Implications - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Pfizer and Bristol-Myers Squibb’s Promising Study on Multiple Myeloma Treatment - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Bristol-Myers Squibb’s New Psoriasis Study: A Long-Term Safety Evaluation - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Anal Cancer Market Is Going to Boom | Major Giants Merck & Co., Roche, Bristol-Myers Squibb, Pfizer - newstrail.com

Aug 14, 2025
pulisher
Aug 13, 2025

Bristol-Myers Squibb stock price target lowered to $45 at Cantor Fitzgerald - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 12, 2025

Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Competitive Analysis of Bristol Myers Squibb, Pfizer, Eli Lilly, Merck, Novartis, Amgen, F. Hoffmann-La RocheResearchAndMarkets.com - Bluefield Daily Telegraph

Aug 12, 2025
pulisher
Aug 12, 2025

Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - uk.finance.yahoo.com

Aug 12, 2025
pulisher
Aug 12, 2025

Can Bristol Myers Squibb Company lead its sector in growthHigh Yield Growth Opportunities - mustnews.co.kr

Aug 12, 2025
pulisher
Aug 11, 2025

Hung Trinh: BioNTech SE and Bristol Myers Squibb Partner on Next-Gen Bispecific Antibody for Solid Tumors - Oncodaily

Aug 11, 2025
pulisher
Aug 11, 2025

Bristol-Myers Squibb’s MYK-224 Study Termination: What Investors Need to Know - MSN

Aug 11, 2025
pulisher
Aug 10, 2025

Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - Oncodaily

Aug 10, 2025
pulisher
Aug 09, 2025

Jim Cramer on Bristol-Myers: “Have Not Been Recommending the Stock” - Insider Monkey

Aug 09, 2025
pulisher
Aug 08, 2025

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Bristol Myers Squibb Named Top Dividend Stock With Insider Buying and 5.47% Yield (BMY) - Nasdaq

Aug 08, 2025
pulisher
Aug 08, 2025

Bristol-Myers Squibb’s Promising Phase 3 Study on BMS-986278: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Bristol Myers Squibb (NYSE:BMY) Cut to Neutral at Daiwa Capital Markets - Defense World

Aug 08, 2025
pulisher
Aug 07, 2025

Car T Cell Therapy For Multiple Myeloma Market Growth to Accelerate in Forecast Period (2024-2032), DelveInsight Analyzes by DelveInsight | Johnson & Johnson, Gadeta, Bristol-Myers Squibb, Bluebird - Barchart.com

Aug 07, 2025
pulisher
Aug 06, 2025

Stock Analysis | Bristol-Myers Squibb OutlookNavigating Weak Technicals Amid Mixed Fundamentals - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

FDA Accepts Breyanzi sBLA from Bristol Myers Squibb and Grants It Priority Review for MZL - BioPharm International

Aug 06, 2025
pulisher
Aug 06, 2025

Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised - Investing.com Nigeria

Aug 06, 2025
pulisher
Aug 06, 2025

Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised By Investing.com - Investing.com South Africa

Aug 06, 2025
pulisher
Aug 05, 2025

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

3 Dividend Stocks for August 2025 - Morningstar

Aug 05, 2025
pulisher
Aug 05, 2025

Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View - MSN

Aug 05, 2025
pulisher
Aug 04, 2025

Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity (NYSE:BMY) - Seeking Alpha

Aug 04, 2025
pulisher
Aug 04, 2025

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327 - insights.citeline.com

Aug 04, 2025
pulisher
Aug 04, 2025

Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb Company (BMY) - Insider Monkey

Aug 04, 2025
pulisher
Aug 04, 2025

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas - Yahoo Finance

Aug 04, 2025
pulisher
Aug 04, 2025

BioNTech shares rise over 2% as Q2 revenue doubles, Bristol Myers deal bolsters outlook - Investing.com

Aug 04, 2025
pulisher
Aug 04, 2025

Bristol-Myers Squibb: Is the 30% Pullback a Strategic Buy Opportunity? - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 22.84% Upside Potential with a Robust Dividend Yield - DirectorsTalk Interviews

Aug 04, 2025

Bristol Myers Squibb Co Stock (BMY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general SNY
$51.35
price up icon 1.46%
$114.77
price down icon 1.18%
drug_manufacturers_general PFE
$25.88
price up icon 0.54%
$293.72
price down icon 0.69%
drug_manufacturers_general NVO
$56.98
price up icon 2.76%
drug_manufacturers_general MRK
$87.37
price up icon 1.50%
Cap:     |  Volume (24h):